Prevest Denpro Limited Annual Report FY 2025-26

Financial Performance Overview

Standalone Financials (₹ in Lakhs):

  • Revenue from Operations: ₹7,166.12 (FY26) vs ₹6,306.77 (FY25) - 13.63% growth
  • Profit Before Tax: ₹2,854.04 (FY26) vs ₹2,427.27 (FY25) - 17.58% increase
  • Profit After Tax: ₹2,141.82 (FY26) vs ₹1,820.13 (FY25) - 17.67% increase
  • Current Assets: ₹10,605.63; Current Liabilities: ₹717.05; Current Ratio: 14.79

Consolidated Financials (₹ in Lakhs):

  • Revenue from Operations: ₹7,181.81 (FY26) vs ₹6,304.97 (FY25) - 13.93% growth
  • Profit After Tax: ₹2,049.05 (FY26) vs ₹1,815.52 (FY25) - 12.86% increase

Key Financial Metrics & Ratios

  • Debt-free balance sheet maintained throughout FY26
  • Exports: Increased by 17.58% YoY, contributing significantly to revenue (₹4,223.46 lakhs)
  • Domestic business: Grew by 9% YoY (₹3,076.47 lakhs)
  • Return on Equity: 17.02% (Standalone), 16.42% (Consolidated)
  • Net Profit Ratio: 29.89% (Standalone), 28.53% (Consolidated)
  • Trade Receivables Turnover: 8.63 times (Standalone), 8.77 times (Consolidated)

Operational Highlights

  • Product Portfolio: Expanded dental materials, Oradox oral care, Prevest 3D printing solutions, and disinfectant products
  • Global Reach: Products exported to over 90 countries across North America, Europe, Asia, Africa, and Middle East
  • Manufacturing Capacity: Installed production capacity exceeding 200 Metric Tonnes per annum
  • Subsidiaries: Three wholly-owned subsidiaries - Denvisio Biomed Limited, Axiodent Inc. (USA), and Prevest Denpro Gulf General Trading L.L.C (UAE)

Strategic Developments

  • UAE Subsidiary: Established Prevest Denpro Gulf General Trading L.L.C to strengthen Middle East operations
  • Disinfectant Business: Successfully commercialized Viro range of disinfectants
  • Digital Dentistry: Expanded Prevest 3D portfolio with advanced digital solutions
  • R&D Initiatives: DSIR-recognized Prevest Research Institute focused on import substitution and new product development
  • Collaborations: MoU with IIT Kanpur for biomaterials research and development

Corporate Actions

Dividend:

  • Recommended final dividend of ₹1 per equity share of face value ₹10 each
  • Dividend payout amount: ₹120.03 lakh

Board Changes:

  • Re-appointments: Mrs. Namrata Modi as Whole-Time Director & CFO, Mr. Sai Kalyan Surapaneni as Executive Director
  • New Independent Directors appointed: Mr. Piyush Kiranprakash Gupta, Mr. Abhijeet Sadashiv Haridas, Mr. Sukhen Pal Babuta
  • Mr. Pratul Gupta appointed as Company Secretary & Compliance Officer

Auditor Appointments:

  • Proposed appointment of M/s. A D V & Associates as Statutory Auditors for 5 years
  • Secretarial Auditors: M/s. NKM & Associates; Internal Auditors: M/s. VNB and Company

Regulatory Compliance Matters

Secretarial Audit Observations:

  • Delayed intimation to BSE regarding director re-appointments
  • Paid excess remuneration of ₹11.38 lakh to Mr. Sai Kalyan Surapaneni without statutory approvals
  • Company proposing to seek shareholder approval for waiver of recovery of excess remuneration

Other Compliance:

  • No fraud reported by any auditors during FY26
  • No material orders passed by regulators/courts affecting going concern status
  • Complied with Sexual Harassment of Women at Workplace Act, 2013 (no complaints received)

Employee Benefits

Gratuity Expenses (Standalone):

  • Current service cost: ₹684; Interest on obligation: ₹289
  • Expected return on plan assets: (₹374); Net actuarial loss: (₹513)
  • Total charge to P&L: ₹86
  • Defined benefit obligation: ₹4,532; Plan assets: ₹5,447; Net liability: (₹915)

Corporate Social Responsibility

  • CSR Expenditure: ₹42.11 lakh spent during FY26
  • Focus Areas: Education promotion, healthcare initiatives, skill development, women empowerment, environmental development
  • Alignment with SDGs: Contributions to Zero Hunger, Good Health, Quality Education, Decent Work, and Reduced Inequalities

AGM Details

  • Date: September 17, 2026
  • Time: 12:30 PM IST
  • Mode: Video Conferencing/Other Audio Visual Means
  • Business: Adoption of financial statements, dividend declaration, director appointments, ratification of auditors, waiver of excess remuneration

Forward Outlook

  • Focus on expanding digital dentistry and disinfectant businesses
  • Strengthening presence in Tier II and Tier III markets
  • Enhancing global footprint through new market entries
  • Investing in R&D for new product development
  • Continuing localization of raw materials to reduce import dependence